Leading Innovation at Intellia
Lunch and Learn
Leading Innovation at Intellia
Laura Sepp-Laurenzino
Chief Scientific Officer, Intellia therapeutics
Wednesday February 19th
12:00-12:45 pm Seminar
12:45-1:15 pm career chat
Albert Sherman AS4-2072
Lunch will be provided
Please RSVP here if you are attending
Laura is currently the chief scientific officer at Intellia Therapeutics, biotech company that develops biopharmaceuticals using CRISPR gene-editing technology. Laura is an innovative leader in drug discovery and development of small molecule and oligonucleotide therapeutics, with over 20 years of experience in academic and industrial settings.
She defines and implements internal and external research strategy, incorporating disruptive, enabling technologies. Dr. Sepp-Lorenzino builds responsive, collaborative teams across geographies and functions and nurtures a learning environment across the organization; coaching, mentoring. She optimizes operations and cost structures, delivering on objectives.
Wednesday, December 11, 2019
Event Description
- What are the potential risks for a bio-pharma start-up? What are the risks for a pharmaceutical company? How do the risks for a start-up and pharma company differ from each-other.
- How does an insurance protect from these risk? For eg- poor management, failure of a Clinical trials, running into losses, accident in a facility, scientific misconduct by an employee.
- Along with the insurance does the company provide guidance and mentor-ship to alleviate some of the risks.
- Attendees will benefit a lot from a case study.
